FDA Approves FAYUVI Gene Therapy, Triggering Milestone Payments for Abeona
ABEO sits 44% above its 52-week low of $4 on elevated volume (2.3× avg).
Summary
The FDA approved Ultragenyx's FAYUVI gene therapy for Sanfilippo syndrome type A, a program Abeona originally developed as ABO-102 and out-licensed in 2022. Under that agreement, Abeona is now eligible for commercial milestone payments and royalties on future sales. This is a meaningful value-creation event for Abeona, validating its foundational R&D and adding a potential revenue stream beyond ZEVASKYN. The approval also de-risks the partnered asset and may improve Abeona's standing in future licensing discussions. Watch for disclosure of milestone amounts or royalty rates in upcoming filings.
At the time of this announcement, ABEO was trading at $5.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $319.7M. The 52-week trading range was $4.00 to $7.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.